October 2, 2023 11:24 AM EDT

Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurx to move to PhIII

Plus, more news from Amicus Therapeutics, Mogrify, and Clade Therapeutics.

Rocket gets a March date with FDA: The FDA has

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II